IPhone / Mobile Compatible

Viewport Meta

Apple Mobile Web Clips Icon

Google Font API

WordPress

Font Awesome

nginx

Wordpress Plugins

Contact Form 7

Senior Vice President, Chief Business Officer

Vivek Shenoy

Sales and Support

Tae-Yon Chun

Hye-Shin Chung

CTO and Co-Founder

Soon Jae Park

Pharmaceutical Companies With More Than 10 Employees (Top 10K)

Asia Pharmaceutical Companies

Private Taejon-jikhalsi Companies

Taejon-jikhalsi Companies

Founded in 2008, Alteogen is a leading bio company whose portfolio includes next-generation Biobetter, with improved efficacy in comparison with existing biologics, biosimilars that demonstrate “comparability” to the existing biologics, and proprietary biologics.
Alteogen focus on the three cutting edge areas of the industry – long-acting biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
Currently, Alteogen has developed NexP™ Fusion Technology, a next-generation long-acting biobetter technology on its own, developed NexMab™ ADC Technology, an Antibody-Drug Conjugate technology, novel human hyaluronidase PH 20 based on Hybrozyme Technology and is jointly developing Antibody Biosimilars with overseas strategic alliance partners.

Series A - Alteogen

Daejeon

Taejon-jikhalsi

South Korea

Asia

Alteogen

Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

MSCI Korea Index adds Alteogen, Enchem, HD Hyundai Electric

Alteogen stock rebounds after ex-CSO sells 3% stake in block deal

Alteogen names MSD as partner in revised, potential $3.8B+ deal

Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile

Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen’s Hybrozyme™ Technology

Phase 1 Clinical Trial of Aflibercept (Eylea®) Biosimilar Completed by Alteogen

Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology

Estonia

Europe

Pakistan

Swiss pharmaceutical company specializing in biosimilar products

Sandoz

Alteogen is a leading bio company specializing in next-generation biobetters, biosimilars, and proprietary biologics. They focus on long-acting biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with high complexity.

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

ALTEOGEN Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Nov 15, 2024 11:51 AM	9732e5f8
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Nov 14, 2024 10:16 AM	a140d920
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:50 PM	acaf90a7
crunchbase profile	general	Oct 29, 2024 6:24 AM	0d8be4fa
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	0d90651e
peers	general
news basic	general	Feb 23, 2024 7:56 PM	854cfb4c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

1961

COM:ALTEOGEN

Alteogen

Last Close

346.50K

22/11 06:30

Market Cap

14.32T

Beta: -

Volume Today

4.65M

Avg: -